GSK

NUCALA

Manufacturer:

GSK

Nucala HCPCS:

J2182

HCPCS Code Descriptor:

Injection, mepolizumab, 1 mg

Category:

J Code

Nucala NDCs:

00173-0892-01, 00173-0892-42, 00173-0881-01, 00173-0904-42

Primary Type:

Anti-Eosinophil Asthma

Generic/Specialty Status:

Single-Source

Route of Administration:

Subcutaneous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Nucala:

NUCALA is an Anti-Eosinophil Asthma drug manufactured by GSK and administered via the Subcutaneous route of administration. The J Code: J2182 is aligned to the drug NUCALA.

Nucala is a maintenance treatment for patients with certain types of severe asthma. Nucala has been shown to help reduce symptoms in patients with a type of asthma called eosinophilic asthma. Nucala is thought to work by reducing levels of eosinophils in the body, a type of white blood cell that can contribute to certain disorders when present in high amounts. It is believed that reducing levels of eosinophils in the body relieves inflammation in the lungs.

ACCESS PRICING AND MORE BY REGISTERING

J2182 Added Date:

January 1, 2017

J2182 Effective Date:

January 1, 2017

J2182 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Nucala billing and coding information.
Nucala patient assistance information can be found through GSK for You at the URL: http://www.gskforyou.com/
NUCALA prescribing information can be found at the link below:
Information regarding NUCALA’s side effects can be found at MedlinePlus